Logo image of CGEM

CULLINAN THERAPEUTICS INC (CGEM) Stock Fundamental Analysis

NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD

7.52  -0.01 (-0.13%)

After market: 7.52 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CGEM. CGEM was compared to 556 industry peers in the Biotechnology industry. CGEM has a great financial health rating, but its profitability evaluates not so good. CGEM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGEM has reported negative net income.
In the past year CGEM has reported a negative cash flow from operations.
In the past 5 years CGEM reported 4 times negative net income.
CGEM had a negative operating cash flow in each of the past 5 years.
CGEM Yearly Net Income VS EBIT VS OCF VS FCFCGEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of CGEM (-30.83%) is better than 64.93% of its industry peers.
Looking at the Return On Equity, with a value of -32.39%, CGEM is in the better half of the industry, outperforming 76.08% of the companies in the same industry.
Industry RankSector Rank
ROA -30.83%
ROE -32.39%
ROIC N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
CGEM Yearly ROA, ROE, ROICCGEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CGEM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGEM Yearly Profit, Operating, Gross MarginsCGEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

CGEM has more shares outstanding than it did 1 year ago.
CGEM has more shares outstanding than it did 5 years ago.
CGEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGEM Yearly Shares OutstandingCGEM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CGEM Yearly Total Debt VS Total AssetsCGEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 7.98 indicates that CGEM is not in any danger for bankruptcy at the moment.
CGEM's Altman-Z score of 7.98 is amongst the best of the industry. CGEM outperforms 83.63% of its industry peers.
CGEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.98
ROIC/WACCN/A
WACCN/A
CGEM Yearly LT Debt VS Equity VS FCFCGEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

CGEM has a Current Ratio of 11.62. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.62, CGEM belongs to the top of the industry, outperforming 82.55% of the companies in the same industry.
CGEM has a Quick Ratio of 11.62. This indicates that CGEM is financially healthy and has no problem in meeting its short term obligations.
CGEM has a Quick ratio of 11.62. This is amongst the best in the industry. CGEM outperforms 82.73% of its industry peers.
Industry RankSector Rank
Current Ratio 11.62
Quick Ratio 11.62
CGEM Yearly Current Assets VS Current LiabilitesCGEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

CGEM shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.03%.
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.04% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.46%
EPS Next 2Y-0.66%
EPS Next 3Y1.51%
EPS Next 5Y-3.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGEM Yearly Revenue VS EstimatesCGEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
CGEM Yearly EPS VS EstimatesCGEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEM Price Earnings VS Forward Price EarningsCGEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEM Per share dataCGEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.66%
EPS Next 3Y1.51%

More info and screens

0

5. Dividend

5.1 Amount

CGEM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (7/21/2025, 4:20:00 PM)

After market: 7.52 0 (0%)

7.52

-0.01 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners110.6%
Inst Owner Change0.01%
Ins Owners1.19%
Ins Owner Change2.06%
Market Cap443.76M
Analysts87.5
Price Target29.45 (291.62%)
Short Float %11.43%
Short Ratio15.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.5%
Min EPS beat(2)5.54%
Max EPS beat(2)9.46%
EPS beat(4)3
Avg EPS beat(4)7.43%
Min EPS beat(4)-1.34%
Max EPS beat(4)16.07%
EPS beat(8)7
Avg EPS beat(8)13.72%
EPS beat(12)9
Avg EPS beat(12)7.85%
EPS beat(16)12
Avg EPS beat(16)7.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.29%
PT rev (3m)-10.81%
EPS NQ rev (1m)-4.83%
EPS NQ rev (3m)-0.63%
EPS NY rev (1m)0%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-3.07
Fwd EYN/A
FCF(TTM)-2.55
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0
BVpS9.35
TBVpS9.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.83%
ROE -32.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.62
Quick Ratio 11.62
Altman-Z 7.98
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.88%
Cap/Depr(5y)267.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.95%
EPS Next Y-9.46%
EPS Next 2Y-0.66%
EPS Next 3Y1.51%
EPS Next 5Y-3.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.96%
EBIT Next 3Y4.07%
EBIT Next 5YN/A
FCF growth 1Y4.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.56%
OCF growth 3YN/A
OCF growth 5YN/A